Development and characterization of solid oral dosage form incorporating candesartan nanoparticles Solid oral dosage form incorporating drug nanoparticles

Pharmaceutical Development and Technology

Volumn 14, Issue 3, 2009, Pages 290-298

  Nekkanti, Vijaykumar ^a   Pillai, Raviraj ^a   Venkateshwarlu, Vobalaboina ^a   Harisudhan, T ^a  

^a DR REDDY'S LABORATORIES LTD   (India)

Author keywords

Bead milling; Candesartan cilexetil; Panoparticles; Particle size; Poorly soluble drugs

Indexed keywords

CANDESARTAN HEXETIL; EXCIPIENT; NANOPARTICLE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BIPHENYL DERIVATIVE; DRUG DOSAGE FORM; TETRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SOLUBILITY; MALE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SOLID STATE; SPRAY DRYING; SUSPENSION; TABLET; ANIMAL; CHEMISTRY; DEVICES; DRUG DOSAGE FORM; EQUIPMENT DESIGN; ORAL DRUG ADMINISTRATION; PROCEDURES; SOLUBILITY; WISTAR RAT;

ADMINISTRATION, ORAL; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; DOSAGE FORMS; DRUG COMPOUNDING; EQUIPMENT DESIGN; MALE; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, WISTAR; SOLUBILITY; TETRAZOLES;

EID: 70350654531     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.1080/10837450802585278     Document Type: Article

References (9)

1. Liversidge GG, Cundy KC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs. Int J Pharm. 1995;125:91-97.
2. Liversidge EM, Liversidge GG, Cooper ER. Nanonizing: a formulation approach for poorly- water-soluble compounds. Eur J Pharm Sci. 2003;18:113-120.
3. Hecq J, Deleers M, Fanara D, Vranckx Boulanger P, Le Lamer S, Amighi K. Preparation and in vitro/in vivo evaluation of nanosized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base. Euro J Pharm Biopharm. 2006;64:360-368.
4. Nogami H, Nagai T, Yotsuyanagi T. Dissolution phenomena of organic medicinals involving simultaneous phase changes. Chem Pharm Bull. 1969;17:499-509.
5. Kesisoglou F, Panmai S, Wu Y. Nanosizing - oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev. 2007;59:631-644.
6. Lee J. Drug nano- and microparticles processed into solid dosage forms: Physical properties. J Pharm Sci. 2003;92:2057-2066.
7. Hecq J, Deleers M, Fanara D, Vranckx , Amighi K. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int J Pharm. 2005;299:167-177.
8. Lee J, Cheng Yu. Critical freezing rate in freeze drying nanocrystal dispersions. J Control Release. 2006;11:185-192.
9. Carlson JA, Mann HJ, Canafax DM. Effect of pH on disintegration and dissolution of ketoconazole tablets. Am J Hosp Pharm. 1983;40:1334-1336.